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Abstract
This paper summarizes information about breast MRI to be
provided to women and referring physicians. After listing
contraindications, procedure details are described, stressing
the need for correct scheduling and not moving during the
examination. The structured report including BI-RADS® cat-
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egories and further actions after a breast MRI examination are
discussed. Breast MRI is a very sensitive modality, signifi-
cantly improving screening in high-risk women. It also has a
role in clinical diagnosis, problem solving, and staging,
impacting on patient management. However, it is not a perfect
test, and occasionally breast cancers can be missed. Therefore,
clinical and other imaging findings (from mammography/ul-
trasound) should also be considered. Conversely, MRI may
detect lesions not visible on other imaging modalities turning
out to be benign (false positives). These risks should be
discussed with women before a breast MRI is requested/per-
formed. Because breast MRI drawbacks depend upon the in-
dication for the examination, basic information for the most
important breast MRI indications is presented. Seventeen
notes and five frequently asked questions formulated for use
as direct communication to women are provided. The text was
reviewed by Europa Donna–The European Breast Cancer
Coalition to ensure that it can be easily understood by women
undergoing MRI.
Key Points
• Information on breast MRI concerns advantages/
disadvantages and preparation to the examination
• Claustrophobia, implantable devices, allergic predisposi-
tion, and renal function should be checked
• Before menopause, scheduling on day 7–14 of the cycle is
preferred
• During the examination, it is highly important that the
patient keeps still
• Availability of prior examinations improves accuracy of
breast MRI interpretation
Keywords Breast . Breast cancer . Magnetic resonance
imaging . Access to information . Patient advocacy
Introduction
Initial results regarding magnetic resonance imaging (MRI) of
the breast were published more than 30 years ago, but clinical
use started during the 1990s after the introduction of contrast-
enhanced (CE) protocols [1, 2]. BreastMRI is today one of the
main methods for diagnosing breast diseases, together with
mammography, ultrasound, and image-guided needle biopsy.
It is based on the use of (a) a strongmagnetic field provided by
a high-quality magnet; (b) low-energy electromagnetic waves
(radiofrequency waves, similar to those of radio, television,
and portable phones) radiated and received by special coils
(antennas) inside the magnet and positioned close to the in-
vestigated body part. MRI can well differentiate lesions and
abnormalities of the breast. However, in order to diagnose or
exclude a cancer, intravenous administration of a gadolinium-
containing contrast material (CM) is needed [3, 4]. Injection of
CM is not required for evaluation of breast implant integrity.
MRI does not expose the patient to potentially dangerous ra-
diation, but other important precautions, contraindications,
and potential side effects (including those regarding CM)
should be considered.
In terms of cancer detection, MRI outperforms (but not
entirely substitutes) both mammography and ultrasound. Its
valuable diagnostic performance has been confirmed bymany
studies. However, MRI also detects benign lesions that would
otherwise have gone unnoticed, leading to additional other-
wise unnecessary work-up. Costs must also be considered, as
MRI is more expensive than mammography and ultrasound.
The main indications for breast MRI [5–9] are listed in
Table 1.
Women’s information is important not only for patient
awareness about advantages and disadvantages of breast
MRI, but also to be prepared for the examination. Patients
need to be aware of the possible benefits and risks associated
with breast MRI and of potential further investigations
prompted by this exam. Moreover, technical quality of breast
MRI is dependent on patient compliance.
This paper is the second of a series of recommendations for
women’s information issued by the European Society of
Breast Imaging (EUSOBI), the first focusing on mammogra-
phy [10]. It is proposed to women and physicians dealing with
patients for whom breast MRI is being considered. In partic-
ular, 17 notes and 5 frequently asked questions are formulated
for use as direct communication to women. As many different
issues are considered, single authors generally agreeing on
these recommendations can have different opinions on indi-
vidual statements. Finally, differences across European coun-
tries are relevant in terms of available technology, national
guidelines, clinical practices, health care system, and insur-
ance coverage. Thus, these recommendations can have differ-
ent applications under local conditions.
Table 1 Indications for breast MRI
Screening of women at high risk of breast cancer
Preoperative staging of newly diagnosed breast cancer (ipsilateral and
contralateral)
Evaluation of the effect of neoadjuvant chemotherapy
Evaluation of women with breast implants
Occult primary breast carcinoma (search for breast cancer in patients with
metastases and negative mammography and ultrasound)
Suspected local recurrence*
Problem solving (equivocal findings at mammography/ultrasound)*
*When needle biopsy cannot be performed
Other new indications were recently proposed, such as nipple discharge
[8] and evaluation of lesions with uncertain malignant potential (so-called
high-risk or B3 lesions) detected at mammography or ultrasound, and
needle-biopsied under their guidance [9]
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Precautions/Contraindications
AnMRI system is a relatively narrow tube in which the wom-
an lies in prone position during a breast examination for 15 to
30 min. Patients with severe claustrophobia are unable to un-
dergo the examinat ion unless they accept to be
psychologically/pharmacologically prepared or sedated [11].
Because of the use of magnetic fields and radiofrequency
waves, the presence of non-MRI compatible intracranial fer-
romagnetic clips for aneurysms and iron splinters in the eyes
are absolute contraindications toMRI. In cases of doubt, anX-
ray examination of the orbits can be performed to rule out the
presence of iron splinters. Moreover, MRI is also contraindi-
cated in patients with implanted electronic devices such as
MR-unsafe pacemakers, implantable cardioverter defibrilla-
tors, and neurostimulators.
The woman should inform the radiologist or the staff per-
sonnel (technicians/nurses) if she has tattoos or permanent
make-up. These may contain iron pigments, and especially
when loop-shaped (like an antenna), they may heat up and
cause local burns. Tissue expanders (e.g. for breast reconstruc-
tions) may not be MR-compatible. Women with intravascular
stents or metal screws or plates for osteosynthesis can safely
have a breast MRI 6 weeks after implantation. A list of im-
plantable devices and precautions needed for MR imaging can
be found on the Internet [12].
As stated above, breast MRI without CM cannot answer
clinical questions [3, 5–7], with the evaluation of breast im-
plant integrity as the only exception. Women with allergic
predispositions or earlier allergic reactions to any CM have a
higher risk for allergic reactions to MRI CM. Moreover, in
women with very poor kidney function (estimated glomerular
filtration rate lower than 30 ml/min×1.73 m2), contrast injec-
tion implies a real, but very low risk of a rare disease called
nephrogenic systemic fibrosis [13]; CE MRI is also generally
contraindicated in pregnant women, but this condition should
be evaluated on a case-by-case basis [14].
Before entering the MRI room, the patient is asked to fill
out a detailed questionnaire to rule out any contraindication to
examination and to CM injection.
Note A. If you think you may be claustrophobic, you
can go to the MR centre and ask to see the MR scanner to
get practical information. If you are seriously claustro-
phobic, discuss this with the referring physician, radiolo-
gist, and personnel of the institution where MRI is sched-
uled. This issue should be discussed and resolved before
attending the examination. The use of a simple sedative
medication to relieve the symptoms might be indicated.
Note B. If you have an implantable device such as pace-
makers/defibrillators, metal implants, or breast ex-
panders, discuss this with referring physician, as these
might imply that MRI could harm you and/or damage
the device. In cases of doubt about contraindication, in-
form the radiologist and the personnel of the institution
where MRI is scheduled. This issue should be discussed
before the MRI takes place. If this information has not
been provided in advance, inform the personnel before
the examination.
Note C. If you have an important allergic predisposition
(e.g. bronchial asthma) or you had allergic reactions to
drugs or CMs before, discuss this with your referring
physician. In cases of serious allergic symptoms, a bal-
ance between the potential advantages of MRI and the
risk of allergic reactions has to be made. Where MRI
has to be performed, precautions need to be taken, includ-
ing the administration of corticosteroid and antihistamin-
ic drugs prior to the investigation. In any case, consult
your radiologist before the scheduled MRI date. We rec-
ommend informing the personnel of the institution where
MRI is scheduled. This issue should be discussed before
MRI takes place.
Note D. To avoid a risk fromMRI CM in the presence of
renal failure, different regulations are adopted in Euro-
pean countries. Your renal function can be checked using
a simple blood test (performed not before 30 days from
MRI) for evaluating your creatinine level and estimating
the glomerular filtration rate. In any case, inform your
referring physician and radiologist if you have a history
of bladder or kidney disease, diabetes mellitus, cardiac or
vascular disease, multiple myeloma, Waldenström dis-
ease, or if you use diuretics or non-steroidal anti-inflam-
matory drugs (e.g. ibuprofen/naproxen).
Scheduling
In premenopausal women, CE MRI is preferentially per-
formed between days 7 and 14 of the menstrual cycle, when
the background enhancement of the normal fibroglandular
breast tissue is low, and hence abnormalities are better detect-
ed and false positives less frequent [15–19]. During the re-
maining days of the menstrual cycle, lesions may be masked
by enhancement of the fibroglandular tissue potentially reduc-
ing the diagnostic value of the examination. If necessary,
breast MRI may be performed in the third week of the men-
strual cycle, taking into consideration that the results could be
suboptimal. The use of oral contraceptives does not contrain-
dicate CE MRI, but the above defined rules should be ob-
served.Womenwith irregular menses (e.g., in perimenopausal
phase) may undergo blood sampling for serum progesterone
to determine the optimal time for breast MRI, especially if
earlier examinations have been non-diagnostic due to strong
glandular enhancement [20]. Premenopausal women who
need only implant integrity evaluation can undergo non-
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contrast breast MRI at any time. All postmenopausal women
can undergo CE MRI at any time. In fact, postmenopusal
hormone replacement therapy has been recently reported to
have negligible effect on parenchymal background enhance-
ment [21]. In any case, breast MRI optimal scheduling should
not substantially delay therapy planning.
Note E. If you are premenopausal and have an appoint-
ment for a screening CE MRI, check your menstrual cy-
cle. If the exam scheduled is not between days 7 and 14
after the first day of your period, contact the centre and try
to reschedule your appointment. If CE MRI has to be
performed for another indication, discuss this with your
radiologist: speed is sometimes more important than ad-
equate scheduling. Be aware that an MRI examination
performed outside the most suitable phase of the cycle
may cause both false positives (findings suspected to be
malignant which turn out to be benign) and false nega-
tives (apparently normal or benign findings when a can-
cer is present). Cycle-related scheduling is not required
for assessing breast implants and CM administration is
not planned.
Note F. If you have irregular menses (e.g. perimeno-
pausal phase) or if you have had a hysterectomy before
50 years of age, consult your radiologist to verify the need
for blood sampling for serum progesterone to determine
the optimal MRI scheduling.
Technique/Procedure
Breast MRI is performed using MRI scanners working at 1.5
or 3 Tesla (1.5 Tesla=15,000 Gauss).
Clear instructions and explanation regarding the pro-
cedure are provided by a technician or a nurse. After a
possible interaction with the radiologist on duty and
completion of questionnaires, if CM injection is needed,
the woman is asked to sign a specific informed consent.
Thereafter, intravenous access is obtained, placing a
small plastic cannula in the cubital vein of one arm, a
simple puncture comparable to that for blood sampling.
During the examination, CM will be injected followed
by a saline flush using an automated injector. The can-
nula will be removed after the procedure and the punc-
ture site will be shortly compressed to stop bleeding.
The woman should keep still during the entire ex-
amination as patient movement causes most artifacts,
which strongly reduce image quality and make inter-
pretation difficult and sometimes impossible. A warm
and sometimes tingling sensation can be felt in the arm
of injection. This may be more extensive and be felt
throughout the body. A metallic taste may occur within
the mouth. A transient headache or nausea may rarely
occur.
The procedure is performed with the upper body un-
dressed and bra removed. Any clothing containing met-
al, jewellery, and other foreign objects must be re-
moved. Some centres require a lmost complete
undressing and provide disposable clothing. Dedicated
breast coils are mandatory. Women are placed prone
on the MRI table with each breast in the recess of the
coil. A technician or a nurse positions the breasts
avoiding folding of breast tissue on the edges of the
coil. In some centres, slight breast compression is ap-
plied to reduce motion artifacts. Rubber ear plugs or
headphones are provided to reduce the scanner noise
during image acquisition. Radiologists and technicians
are able to communicate with the woman during the
examination. An alarm bell is provided; when it is rung
by the woman, the examination will be terminated im-
mediately and she will be removed from the magnet.
Thus, the woman can be sure that if needed, she will
be assisted.
When the woman is optimally positioned, table and
patient are moved into the magnet, so that her breasts
are in the centre of the tube: the magnetic field is most
homogeneous at that position allowing for optimal im-
age quality. The procedure is noisy, even though ear
plugs/headphones attenuate noise perception. During
the examination, the staff are discouraged from talking
to the woman, as this frequently induces movements
and should be done only when really needed. Scan se-
quences produce different noises and different noise
levels, more relevant being those for CE imaging (con-
tinuous and buzzing sound), and for the so-called diffu-
sion-weighted images (high beeping sound). When
breast implant integrity has to be evaluated, dedicated
scan sequences with different noises are used.
When the examination is done, the table and the woman are
taken out of the scanner, and the table is lowered. The woman
is then asked to sit up to remove the venous access. The pro-
cedure commonly takes 15–30 min, except when additional
sequences are done for clinical purposes. The radiologist can
decide to postpone the removal of the venous access for 10–
15 min before the patient leaves the department (see below).
Note G. During the examination, it is of paramount
importance that you keep still. When the scanner ac-
quires data (the Bsequence^), you hear a relatively strong
noise, reduced by the ear plugs/headphones. You may
think that movements between the different sequences
do not reduce image quality. However, as images ac-
quired over time will be subtracted from each other, also
movements between different scan sequences should be
avoided.
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After the procedure
When the procedure is over, the woman redresses. If CM had
been administered, outpatients may be asked to remain in the
department for about 10–15 min to check for any very rare
delayed reaction to CM. Prior to reading images, image co-
registration using special software is sometimes used, and the
evaluation itself, including previous examinations and clinical
records, also takes time. The report is usually generated within
a few days, but particular cases can require a longer time. In
the case of artifacts or strong enhancement of background
glandular tissue in women not examined in the best phase of
the menstrual cycle or with unexpected other hormonal influ-
ences, a repeat breast MRI can be required. Depending on the
findings and the indication for MRI, additional investigations
may be necessary.
Breast MRI report and BI-RADS® categories
Evaluation of breast MRI should be performed by a dedicated
breast radiologist. The report should contain the indication for
the scan, relevant clinical information, and type and dose of
administered CM. In premenopausal women, the day or the
week of the menstrual cycle on which MRI was performed
should be stated. Techniques used should be very briefly
summarized.
Reported image findings include breast density, amount of
parenchymal background enhancement, and a usually struc-
tured description of relevant abnormalities, including those in
the axillae or incidental findings in the imaged part of thorax
and abdomen, when visible. Side and location of any breast
lesions should be described. Lymph node evaluation is not a
specific aim of breast MRI, but it is possible that the exam
reveals unsuspected nodal metastasis.
Each report should end with a conclusion, commonly as-
sociated with a diagnostic category and recommendations. In
many European countries, a structured reporting and classifi-
cation system is in use. The most commonly applied system is
the Breast Imaging Reporting and Data System (BI-RADS®)
developed by the American College of Radiology [22], also
used with high-resolution 3 T systems [23].
Conclusive BI-RADS diagnostic categories are used as
follows:
& 0 = incomplete, additional imaging evaluation is needed;
& 1 = negative, no abnormalities;
& 2 = benign findings;
& 3 = probably benign findings (short-term follow-up within
6 months recommended; needle biopsy may be performed
only in special cases, such as on patient request or high-
risk patients);
& 4 = suspected malignancy (needle biopsy recommended);
& 5 = highly suspected malignancy (needle biopsy
recommended);
& 6 = already histologically proven cancer (typically re-
served for MRI scans made for cancer staging or in the
case of neoadjuvant chemotherapy).
Recommendation of needle biopsy for BI-RADS 4-5
lesions is a general rule for isolated newly diagnosed
lesions. It could not be performed in the case of a
lesion adjacent or close to a lesion already known to
be cancer. Around 60 % of lesions initially detected at
MRI are identified with second-look targeted ultrasound
[24], even though this rate is variable among studies.
The definition of second-look comes from the common
event that a lesion undetected at first-look ultrasound is
detected at the second look, when the radiologist knows
from MRI where to look. In that case, needle biopsy is
performed under ultrasound guidance, a faster, less in-
vasive, and cheaper procedure than MR-guided biopsy
[25]. When the lesion is not detected with ultrasound
and the indication for biopsy still stands, an MR-
guided biopsy is indicated. It takes longer than a diag-
nostic breast MRI, and it is a special procedure, requir-
ing dedicated targeting and sampling equipment as well
as trained personnel. In some countries it is necessary to
apply for a specific reimbursement (this is a relatively
new and expensive procedure).
However, in the case MR-guided biopsy cannot be per-
formed (e.g., dedicated equipment not available; lesion site
not accessible, such as those very close to the thoracic wall),
computed tomography-guided biopsy or MR-guided
presurgical localization may be performed.
Note H.When a needle biopsy is indicated for anMR-
detected finding, this doesn’t mean you have cancer.
Up to 50–70 % of MRI findings that require biopsy turn
out to be benign [26]. Targeted ultrasound, re-evaluation
of mammograms, targeted mammographic views, or im-
ages obtained with digital breast tomosynthesis are use-
ful, offering the possibility of a biopsy under ultrasound
or mammography guidance. Thus, if a suspicious lesion
(BI-RADS 4 or 5) is MR-detected, an image-guided nee-
dle biopsy should be performed in almost all the cases.
Definition of the benign nature of an MR-detected suspi-
cious finding using only other targeted imaging modali-
ties without biopsy is only possible in very few cases.
Note I. In the case of MRI BI-RADS 4-5, even if
targeted ultrasound and above described mammo-
graphic approaches are negative, cancer cannot be
excluded: an MR-guided biopsy is required. Not all cen-
tres that perform breast MRI offer MR-guided breast bi-
opsy. However, your radiologist should be able to refer
you to a centre where MR-guided biopsy can be
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performed or to opt for needle sampling under computed
tomography guidance or for MR-guided presurgical
localization.
BI-RADS 3 findings form a special diagnostic category
[27], with a chance to be malignant below 2% [28]. However,
the actual chance of an MR-detected BI-RADS 3 lesion being
malignant is sometimes higher, especially in high-risk women
[29]. For a BI-RADS 3 lesion, short-term follow-up is recom-
mended instead of biopsy due to the low malignancy proba-
bility and the expected not reduced treatment efficacy for a
shortly delayed diagnosis. This implies repeat MRI examina-
tions within 6 months and potential further repeat MRI at
1 year and 2 years after initial detection. When, at MRI fol-
low-up, anMR-detected lesion disappears, shrinks, or remains
unchanged in size, and does not show any new sign of malig-
nancy, it can be downgraded to benign (BI-RADS 2) without
biopsy. However, in some cases, mostly when the patient pre-
fers an immediate conclusion of the diagnostic pathway, a
needle biopsy can be directly performed for a BI-RADS 3
lesion.
Note J. In the case of MRI BI-RADS 3 finding, you
should discuss with your radiologist and/or referring phy-
sician whether watchful waiting with a follow-up breast
MRI within 6 months or biopsy should be preferred. Cau-
tion is given in high-risk women: in these women a BI-
RADS 3 finding has a higher probability of malignancy
and biopsy is more frequently performed.
Sensitivity of breast MRI
Overall sensitivity of breast MRI for breast cancer is approx-
imately 90 %, which implies that 10 % of cancers may be
missed. Missed cancers are in general either very small or do
not have enough contrast enhancement. Sensitivity for ductal
carcinoma in situ (DCIS), a noninvasive lesion, possibly a
precursor of invasive cancer and similarly treated, is variable;
some of them, especially those with a lower pathological
grade (G1) can bemissed [30–32]. Occasionally, also invasive
cancers can be occult at MRI. DCIS may be depicted on
mammograms as a cluster of microcalcifications, even if, in
some cases, MRI findings are negative. This implies that find-
ings from clinical examination, mammography, or ultrasound,
even if only probably benign, i.e. BI-RADS 3, should be
reviewed based upon negative MRI findings [33]. Generally,
if a needle biopsy is correctly indicated, a negative MRI find-
ing cannot substitute for biopsy. Of note, sensitivity also de-
pends on technical prerequisites, clinical indication, and read-
er experience.
Note K. If a needle biopsy based upon palpable ab-
normalities or mammography/ultrasound is indicat-
ed, you should have a needle biopsy to rule out cancer.
Even though highly sensitive, breast MRI is not a perfect
test and should not be used as an alternative for biopsy.
Needle biopsies are performed to exclude the presence of
cancer; as a consequence, when a biopsy is recommend-
ed, this does not mean that you have a cancer.
Breast MRI for screening
Due to its high sensitivity, breast MRI is an excellent screen-
ing tool. In cohorts of womenwith a familial increased risk for
breast cancer, and of women who are carriers of BRCA1,
BRCA2, or other rarer gene mutations, the superior sensitivity
of breast MRI compared to other breast imaging techniques
has been shown [7, 34–39]. However, MRI also has a very
high sensitivity for benign breast disease. This leads to addi-
tional investigations, including repeat MRI scans, targeted ul-
trasound, and biopsy, as stated above. This additional burden
from MRI screening is greater in women with a priori lower
breast cancer risk. Moreover, MRI is a relatively expensive
examination, and the need for additional investigations further
increases the cost. Consequently, the cost-effectiveness of
MRI screening has been questioned for women who are not
at increased risk [40]. Note that healthcare reimbursement of
breast MRI screening is variable among countries.
Evidence for a substantial added value of MRI as a screen-
ing tool exists for women with proven BRCA1, BRCA2, or
other rarer gene mutations [7, 34–39], for a proportion of
women with an elevated risk based upon their family history,
and for those patients who received thoracic radiotherapy be-
fore the age of 30 years [41–43]. A recent individual patient-
data meta-analysis showed that for BRCA mutation carriers,
the gain in sensitivity is relevant also over the age of 50 years
[44]. Guidelines throughout Europe and the United States dif-
fer substantially for the risk level deserving breast MRI
screening and the age for starting and ending MRI screening.
Note L. If you have multiple cases of breast and/or
ovarian cancer in your family, discuss the possibility
of MRI screening with your referring physician and your
radiologist. There are risk assessment systems available
to estimate your risk. The referring physician or your
radiologist could decide to refer you to a specialized cen-
tre for risk evaluation. The results thereof can subsequent-
ly be matched to your local/national guideline. Note that
healthcare reimbursement is variable among countries.
Note M. If you were treated with thoracic radiation ther-
apy, discuss the need of MRI and mammography
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screening with your referring physician, radiation therapy
specialist, and radiologist.
Breast MRI for breast cancer staging
Most breast cancers are detected due to clinical symptoms or
by screening mammography. The standard way to assess sus-
picious lesions is with the so-called triple assessment: mam-
mography, ultrasound, and image-guided needle biopsy. MRI
is not yet involved in initial cancer detection except in those
women, usually at high risk, screened with MRI. When
a breast cancer is detected, MRI may be performed to assess
disease extent, look for satellite lesions, and screen for other
cancers either in the affected or in the contralateral breast.
MRI is much better in tumour extent evaluation than either
mammography or ultrasound, even though tumour size over-
estimation and underestimation still occur in up to 15 % of
patients. Although a better documentation of tumour size and
extent could lead to a better tailored surgery, with a low rate of
re-interventions for positive resection margins, randomized
studies that evaluated the surgical outcome of preoperative
MRI gave conflicting results [45–48]. In patients with inva-
sive lobular carcinoma, a specific diffuse growing tumour type
notoriously underestimated by mammography and ultra-
sound, a reduction of re-excisions from 18 % to 11 % was
observed [49], although this was not statistically significant in
a meta-analysis [50]. Other suggested indications are discrep-
ancy in tumour size among different modalities (including
clinical examination) that may change the treatment strategy,
breast cancer found in a high-risk woman, and eligibility for
partial breast irradiation [7, 51].
Preoperative MRI also detects many additional enhancing
lesions unseen with mammography and ultrasound. Approxi-
mately 50 % of them are cancerous (increased up to 75 % in
the breast harbouring an already known malignancy), indicat-
ing that pathological verification is necessary, especially when
the additional lesions are distant from the already diagnosed
cancer. When additional disease is detected, this logically
leads to more extensive surgery. However, this must be
regarded with caution. It should be understood that breast
conserving surgery in breast cancer in over 40 % of patients
is primarily aimed at reducing disease extent rather than being
completely curative [52]. This information should be present-
ed to patients: treatment is mostly completed by radiation
therapy, chemotherapy, and/or hormonal therapy. Conse-
quently, additional MRI-detected tumour foci may be effec-
tively treated by these adjuvant therapies. Extension of sur-
gery indicated by MRI might, therefore, be unnecessary. So
far, there is lack of evidence of improved overall or disease-
free survival due to preoperative MRI. In any case, the possi-
ble patient gain from preoperative MRI is also dependent on
the experience of the radiologist reporting the MRI, the accu-
racy of mapping MR-detected additional tumour extent, capa-
bilities of the treating surgeon using the results of this imaging
technique and thus on the interface between radiology and
surgery.
In addition, MRI detects unsuspected cancer in the contra-
lateral breast in approximately 3 % of all women with unilat-
eral cancer as found by conventional imaging [53], even
though higher rates of contralateral otherwise undetected can-
cers were reported [54]. Since no radiation therapy is given to
the contralateral breast, the detection of unsuspected contra-
lateral cancer may bemore relevant than detection of addition-
al ipsilateral foci. Although in most circumstances the even-
tual prognosis is mainly dictated by the size and grade of the
largest cancer, early detection of second cancers is associated
with a slight increase in survival, especially in patients below
50 years of age [55, 56].
Note N. In the case of a newly diagnosed breast cancer,
preoperative MRI is a possibility for improving treat-
ment of the already diagnosed cancer and also detecting
cancer in the contralateral breast. This must be balanced
against a risk that more extensive unnecessary surgery
may be performed (e.g. mastectomy instead of a lumpec-
tomy) as a consequence of MRI. Your radiologist and
your surgeon can discuss with you potential advantages
and disadvantages of preoperative MRI considering your
particular case.
Breast MRI in patients with implants
MRI is the most sensitive technique to detect breast implant
ruptures when an appropriate protocol is performed [57]. This
protocol includes specialized sequences without CM
administration.
Notably, the usual reaction to breast augmentation is to
form a fibrous capsule around the implant. This capsule fre-
quently keeps the silicone in place even after an implant rup-
ture. In fact, up to 50% of old implants are leaky 10 years after
implantation [58], usually without any symptoms. Thus,
screening for implant rupture is not needed [7]. In symptom-
atic patients, for example, those with an extracapsular rupture
(i.e. with silicone outside the fibrous capsule), the leakage and
spread of silicone in the breast can be very accurately depicted
with MRI. MRI is able to confirm or exclude rupture when
mammography or ultrasound are inconclusive. This may fa-
cilitate the decision of the surgeon tomake a revision and/or to
change the implants.
The presence of implants does not affect the sensitivity of
MRI for breast cancer detection: other indications for CE
breast MRI remain valid in the presence of implants.
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Note O. In the absence of symptoms, breast implants
do not need to be screened for integrity with breast
MRI.However, in cases of suspected rupture, MRI is the
best technique to detect possible leakage.
Note P. Breast implants do not affect the sensitivity of
CE MRI for new or recurrent breast cancer.
Note Q. If you have breast implants and a breast MRI
is planned, remember to bring with you detailed in-
formation about the model/type of the implants you
have. If you don’t have this information, please ask the
surgeon to give you these data.
Evaluation of the effect of neoadjuvant
chemotherapy
In the case of advanced breast cancer, many centres adopt
protocols for reduction of the mass with neoadjuvant chemo-
therapy before surgery. In this setting, MRI is proposed for
either early prediction of response during chemotherapy [59]
or for presurgical evaluation [60, 61]. A baseline MRI evalu-
ation should be performed prior to neoadjuvant chemotherapy,
as MRI images cannot be compared to initial mammography
or ultrasound studies. For both early response prediction and
presurgical evaluation, MRI seems to be a better test than
clinical breast evaluation, mammography, or ultrasound.
However, women should be aware that if MRI is used to guide
surgery at the end of chemotherapy, a fraction of patients (10–
20 %) may have clinically relevant underestimation or over-
estimation of residual cancer [7].
Occult primary breast carcinoma
After the initial detection of metastases, breast cancer may be
suspected, especially when axillary nodes are involved. How-
ever, in a small fraction of patients, in whom needle biopsy of
lymph nodes confirms the breast origin of the disease, mam-
mography and ultrasound are negative. This is occult primary
breast cancer, accounting for up to 1 % of breast cancers. In
this clinical setting, MRI can identify the primary breast can-
cer in about two thirds of cases, allowing for breast conserving
surgery [6, 7, 62]. If breast MRI is negative, immediate sur-
gery may be avoided. In cases of axillary metastases, patients
are usually treated with radiotherapy to the ipsilateral breast.
Follow-up MRI can be proposed [7].
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